GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XBiotech Inc (NAS:XBIT) » Definitions » Debt-to-EBITDA

XBIT (XBiotech) Debt-to-EBITDA : -0.57 (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is XBiotech Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

XBiotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $10.00 Mil. XBiotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.00 Mil. XBiotech's annualized EBITDA for the quarter that ended in Sep. 2024 was $-17.46 Mil. XBiotech's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was -0.57.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for XBiotech's Debt-to-EBITDA or its related term are showing as below:

XBIT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.21   Med: 0   Max: 0
Current: -0.21

XBIT's Debt-to-EBITDA is ranked worse than
100% of 270 companies
in the Biotechnology industry
Industry Median: 1.41 vs XBIT: -0.21

XBiotech Debt-to-EBITDA Historical Data

The historical data trend for XBiotech's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XBiotech Debt-to-EBITDA Chart

XBiotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

XBiotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -0.24 -0.17 -0.57

Competitive Comparison of XBiotech's Debt-to-EBITDA

For the Biotechnology subindustry, XBiotech's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XBiotech's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XBiotech's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where XBiotech's Debt-to-EBITDA falls into.



XBiotech Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

XBiotech's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -35.766
=0.00

XBiotech's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(10 + 0) / -17.456
=-0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


XBiotech  (NAS:XBIT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


XBiotech Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of XBiotech's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


XBiotech Business Description

Traded in Other Exchanges
N/A
Address
5217 Winnebago Lane, Austin, TX, USA, 78744
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.
Executives
Angela Hu officer: Principle Financial Officer 5217 WINNEBAGO LN, AUSTIN TX 78744
John Simard director, 10 percent owner 8201 E RIVERSIDE DRIVE, BLDG 4, STE 100, AUSTIN TX 78744
Bay Street Financial S.a. 10 percent owner MEIERHOFSTRASSE 5, LIECHTENSTEIN N2 9490 VADUZ
W Thorpe Mckenzie director, 10 percent owner 735 BROAD ST, STE 1105, CHATTANOOGA TN 37402
Sushma Shivaswamy officer: VP of R&D 8201 E RIVERSIDE DRIVE, BLDG 4, STE 100, AUSTIN TX 78744
Queena Han officer: VP of Fin & HR, Secretary 8201 E RIVERSIDE DRIVE, BLDG 4 STE 100, AUSTIN TX 78744
Thomas Gut 10 percent owner CO LINDENBERG FAMILY OFFICE LTD, LATERNENGASSE 5, ZURICH V8 8001
Peter Libby director 109 LARCH ROAD, CAMBRIDGE MA 02138
Fondation Rennes 10 percent owner RATIKONSTRASSE 13, VADUZ, PRINCIPALITY OF LIECHTENSTEIN N2 FL-9490
Donald H. Macadam director 56 KELLY DRIVE, PORT DOVER A6 N0A 1N5
Jan-paul Waldin director 77 KING STREET WEST, SUITE 3000, TORONTO A6 M5K 1G8
Benjamin Guzman officer: Sr.VP Corp. Strategy & Finance 8201 E RIVERSIDE DR BLDG. 4 STE 100, AUSTIN TX 78744
Trey Benson officer: VP of Commercial Development 8201 E. RIVERSIDE DR., BUILDING 4, SUITE 100, AUSTIN TX 78744
Kalidip Choudhury officer: VP of Business Development 8201 E. RIVERSIDE DRIVE, BUILDING 4, SUITE 100, AUSTIN TX 78744
Dawn Mccollough officer: VP Clinical Operations 115 SANDRA MURAIDA WAY, #838, AUSTIN TX 78703